Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study | Synapse
February 8, 2026Open Access
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Key Points
To assess the effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis.
Conducted a multicentric study in Italy
Followed adult patients with facial and/or genital psoriasis
Evaluated treatment effects over 52 weeks
Guselkumab showed high effectiveness in reducing psoriasis symptoms
A good safety profile was observed during the treatment period
Abstract
This Italian real-world study demonstrated the high effectiveness and a good safety profile of guselkumab in treating facial and genital psoriasis.